Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder

Patent metadata

Field	Value
Publication number	US-11779577-B2
Application number	US-202117175101-A
Country	US
Kind code	B2
Filing date	Feb 12, 2021
Priority date	Sep 7, 2016
Publication date	Oct 10, 2023
Grant date	Oct 10, 2023

Abstract

This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).

First claim

What is claimed is:

1. A method of treating anorexia nervosa (AN) in a subject with attention deficit hyperactivity disorder (ADHD), the method comprising administering fasoracetam to the subject.

2. The method of claim 1 , wherein the fasoracetam is fasoracetam monohydrate.

3. The method of claim 1 , wherein the fasoracetam is administered at a dose of 50-400 mg and wherein the dose is administered once, twice, or three times daily.

4. The method of claim 1 , wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily.

5. The method of claim 1 , wherein the subject has at least one genetic alteration in a metabotropic glutamate receptor (mGluR) network gene.

6. The method of claim 5 , wherein the genetic alteration is a copy number variation (CNV).

7. The method of claim 6 , wherein the CNV is a deletion.

8. The method of claim 6 , wherein the CNV is a duplication.

9. The method of claim 5 , wherein at least one of the following applies:
(i) the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes;
(ii) the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 2 mGluR network genes; or
(iii) the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 3 mGluR network genes.

10. The method of claim 5 , wherein the genetic alteration is not in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

11. The method of claim 1 , wherein the subject has the bingeing and/or purging subtype of AN.

12. The method of claim 1 , wherein the subject has the restricting subtype of AN.

13. The method of claim 1 , wherein the subject is a pediatric or adolescent subject.

14. The method of claim 1 , wherein the subject is an adult subject.

15. The method of claim 1 , wherein the subject is already taking or is administered one or more of an antidepressant, an anxiolytic or an anti-psychotic.

16. The method of claim 15 , wherein the antidepressant is fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, a tricyclic antidepressant, a selective serotonin reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a norepinephrine and dopamine reuptake inhibitor, or a monoamine oxidase inhibitor.

17. The method of claim 15 , wherein the anxiolytic is a barbiturate, pregabalin, or a benzodiazepine.

18. The method of claim 15 , wherein the anti-psychotic is olanzapine, quetiapine, aripiprazole or risperidone.

19. The method of claim 1 , wherein the fasoracetam is administered in combination with non-pharmaceutical therapy selected from vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetic seizure therapy, and deep brain stimulation.

Assignees

• Childrens Hospital Philadelphia

Inventors

• Hakonarson Hakon
• Kao Charily

Classifications

• A61K31/454 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title